Well, the stock is clearly more attractive today than it was yesterday.
The notion that Iclusig won’t sell in the second-line setting at community onc centers is off-base, IMO; if ARIA’s sales reps can’t sell Iclusig to these docs with the label they have, they should think about changing careers!